company background image
ICPT

Intercept Pharmaceuticals NasdaqGS:ICPT Stock Report

Last Price

US$17.88

Market Cap

US$531.3m

7D

-7.2%

1Y

-1.5%

Updated

15 May, 2022

Data

Company Financials +
ICPT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

ICPT Stock Overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.

Intercept Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Intercept Pharmaceuticals
Historical stock prices
Current Share PriceUS$17.88
52 Week HighUS$22.36
52 Week LowUS$11.60
Beta1.27
1 Month Change8.56%
3 Month Change20.40%
1 Year Change-1.49%
3 Year Change-79.31%
5 Year Change-84.07%
Change since IPO-7.84%

Recent News & Updates

May 10
Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) shareholders will have a reason to smile today, with the analysts...

Shareholder Returns

ICPTUS BiotechsUS Market
7D-7.2%0.1%-2.5%
1Y-1.5%-21.7%-10.4%

Return vs Industry: ICPT exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: ICPT exceeded the US Market which returned -10.4% over the past year.

Price Volatility

Is ICPT's price volatile compared to industry and market?
ICPT volatility
ICPT Average Weekly Movement10.7%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: ICPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ICPT's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002437Jerry Dursohttps://www.interceptpharma.com

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development.

Intercept Pharmaceuticals Fundamentals Summary

How do Intercept Pharmaceuticals's earnings and revenue compare to its market cap?
ICPT fundamental statistics
Market CapUS$531.27m
Earnings (TTM)-US$68.29m
Revenue (TTM)US$370.39m

1.4x

P/S Ratio

-7.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ICPT income statement (TTM)
RevenueUS$370.39m
Cost of RevenueUS$3.05m
Gross ProfitUS$367.34m
Other ExpensesUS$435.63m
Earnings-US$68.29m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.30
Gross Margin99.18%
Net Profit Margin-18.44%
Debt/Equity Ratio-192.8%

How did ICPT perform over the long term?

See historical performance and comparison

Valuation

Is Intercept Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ICPT ($17.88) is trading below our estimate of fair value ($355.65)

Significantly Below Fair Value: ICPT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ICPT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ICPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ICPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ICPT has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Future Growth

How is Intercept Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


71.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ICPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ICPT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ICPT's is expected to become profitable in the next 3 years.

Revenue vs Market: ICPT's revenue (22.3% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: ICPT's revenue (22.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ICPT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Intercept Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


18.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ICPT is currently unprofitable.

Growing Profit Margin: ICPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ICPT is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.

Accelerating Growth: Unable to compare ICPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: ICPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Intercept Pharmaceuticals's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ICPT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ICPT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ICPT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ICPT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ICPT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ICPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Intercept Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ICPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ICPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ICPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ICPT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ICPT has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Jerry Durso (53 yo)

1.33yrs

Tenure

US$7,870,354

Compensation

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD7.87M) is above average for companies of similar size in the US market ($USD2.65M).

Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ICPT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: ICPT's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Intercept Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Intercept Pharmaceuticals, Inc.
  • Ticker: ICPT
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$531.269m
  • Shares outstanding: 29.71m
  • Website: https://www.interceptpharma.com

Number of Employees


Location

  • Intercept Pharmaceuticals, Inc.
  • 10 Hudson Yards
  • 37th Floor
  • New York
  • New York
  • 10001
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.